Form 4: Teva Pharmaceutical Executive VP Richard Daniell Reports Share Sales and Option Exercises
SEC Form 4 Filing
Executive VP of European Commercial at Teva Pharmaceutical Industries, Richard Daniell, reports exercising restricted share units and selling ordinary shares on March 3 and 4, 2025, under a pre-arranged trading plan.
Summary
- Richard Daniell, Executive VP of European Commercial at Teva Pharmaceutical Industries, reported transactions involving Teva's ordinary shares.
- On March 3, 2025, Daniell exercised 62,250 restricted share units, converting them into ordinary shares.
- Also on March 3, 2025, Daniell sold 49,314 ordinary shares at a weighted average price of $16.1855 per share.
- On March 4, 2025, Daniell sold an additional 12,936 ordinary shares at a weighted average price of $15.5576 per share.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on November 19, 2024.
- Following these transactions, Daniell still beneficially owns 12,936 ordinary shares and 124,503 restricted share units.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transactions were part of a pre-planned trading arrangement. It doesn't necessarily reflect a positive or negative outlook on the company's future.
Industry Context
Executive share sales are a common occurrence in publicly traded companies, often executed under pre-arranged trading plans to avoid accusations of insider trading. The market typically analyzes these transactions to gauge executive sentiment, although sales under 10b5-1 plans are less indicative of sentiment.
Stakeholder Impact
- The share sales could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
- The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2023/03/03 | Restricted share units were granted. |
| 2024/11/19 | Rule 10b5-1 trading plan adopted by the reporting person. |
| 2025/03/03 | Date of earliest transaction; exercise of restricted share units and sale of ordinary shares. |
| 2025/03/04 | Sale of ordinary shares. |
| 2025/03/05 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.